Receive Top News Alerts in your E-mail box! >> Learn more
July 18, 2002

Alert: DEA Moves to Schedule 2C-T-7

Addendum Sept. 2002: 2C-T-7 Scheduled.

(In another notice also published today, the DEA declared its intention to place the drugs BZP and TFMPP into Schedule I. To read that notice, see 67 Federal Register 47341-47343, July 18, 2002).)

The US Drug Enforcement Administration today published notice that it intends to place the drug 2C-T-7 into Schedule I of the Controlled Substances Act. 

2C-T-7 is being scheduled pursuant to the DEA’s emergency scheduling powers, meaning that the scheduling could take effect in as early as 30 days (August 17, 2002).

The DEA’s notice states the factual basis behind its decision to schedule 2C-T-7. 

To the extent that any of the information relied upon by the DEA may be inaccurate, the Center for Cognitive Liberty & Ethics (CCLE) and the Multidisciplinary Association for Psychedelic Studies (MAPS) are seeking your help in correcting the record.

If you spot errors in the following notice, please immediately send corrections (supported by citations to published scientific papers) to the CCLE at:

Center for Cognitive Liberty & Ethics
e-mail: info@cognitiveliberty.org
fax: 530-750-7912

Below is the DEA’s factual basis for placing 2C-T-7 in Schedule I. The DEA's complete notice is available at (67 Federal Register 47343-47345). 

** begin DEA quote **

What Is 2,5-Dimethoxy-4-(n)-propylthiophenethylamine?

    2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), a 
phenethylamine, is structurally related to the Schedule I 
phenethylamine 4-bromo-2,5-dimethoxyphenethylamine (2C-B), and other 
hallucinogens (e.g., 2,5-dimethoxy-4-methylamphetamine (DOM), and 1-(4-
bromo-2,5-dimethoxyphenyl-2-aminopropane (DOB)) in Schedule I of the 
CSA. 2C-T-7 has those structural features of phenethylamines which are 
necessary for stimulant and/or hallucinogenic activity; 2C-T-7 is a 
sulfur analogue of 2CB. Based on these structural features. 2C-T-7 is 
likely to have a pharmacological profile similar to 2CB and other 
Schedule I hallucinogens. The similarity in the effects of 2C-T-7 and 
2CB has been supported by Shulgin and Shulgin (Pikal: A Chemical Love 
Story; pp. 569-570, 1991) and by ``self-reports'' on the Internet. 
Shulgin and Shulgin (1991) reported that at an oral dose of 20 mg or 30 
mg, 2C-T-7 produced visual hallucinations. They concluded that in terms 
of being an acceptable hallucinogen, 2C-T-7 was comparable to 2CB and 
mescaline. Self-reports on the Internet have described the 
hallucinations resulting from the self-administration of 2C-T-7 as 
being very 2CB-like; consisting of persistent multiple images, overlaid 
patterns, and trails. The subjective effects of 2C-T-7 have also been 
described as being similar to those of 2CB; mood lifting, sense of well 
being, emotionally, volatility, increased appreciation of music, and 
psychedelic ideation.
    DEA is not aware of any approved therapeutic use of 2C-T-7 in the 
United States. The safety of this substance for use in humans has never 
been demonstrated.
 

What Information Was Considered in Respect to Making the Finding of 

Imminent Hazard to the Public Health?

 

    DEA, as required by 21 U.S.C. 811(h)(3), considered the following 
three factors set forth in paragraphs (4), (5) and (6) of 21 U.S.C. 
811(c) in its decision to temporarily schedule 2C-T-7. The information 
relevant to the three factors is summarized below.
 

21 U.S.C. 811(c)(4) Its History and Current Pattern of Abuse

 

    The abuse of stimulant/hallucinogenic substances in popular all 
night dance parties (raves) and in other venues has been a major 
problem in Europe since the 1990s. In the past several years, this 
activity has spread to the United States. The Schedule I controlled 
substance MDMA and its analogues, collectively known as Ecstasy, are 
the most popular drugs abused at these raves. Their abuse has been 
associated with both acute and long-term public health and safety 
problems. These raves have also become venues for the trafficking and 
abuse of ``new non-controlled'' substances in place of or in addition 
to ``Ecstasy.'' 2C-T-7 is one such substance.
    Illicit use of 2C-T-7 was first reported in Germany in 1997. 2C-T-7 
was placed under the control of German law on January 20, 1998. In 
October of 1999, 2C-T-7 tablets were being sold in the Netherlands 
under the trade name ``Blue Mystic''. Illicit use of 2C-T-7 was 
reported in Sweden in January of 2000. Currently 2C-T-7 is controlled 
under the Swedish law pertaining to goods which are dangerous to the 
public. French Customs authorities reported seizing tablets in 2001 
that contained 10 mg of 2C-T-7.
    Abuse of 2C-T-7 in the United States was first reported in 1997; an 
individual posted his experience associated with the oral ingestion of 
20 mg of 2C-T-7 on the Lycaeum website on the Internet. In the year 
2000, the abuse of 2C-T-7 by young adults began to spread in the United 
States as evidenced by widespread discussion on drug website forums and 
the sale of the substance from an Internet company. The information 
being discussed on these websites includes the route of administration, 
recommended doses, and narratives from individuals describing their 
experiences and effects after self-administering 2C-T-7.
    Self-reported experiences and other information posted on these 
websites indicate that 2C-T-7 is being abused orally (10-50 mg) or 
intranasally; the
 

[[Page 47344]]
 

oral route is the most common route of abuse. The powder is being mixed 
in liquids or placed in gelatin capsules. Information posted on these 
websites indicates that 2C-T-7 is being taken alone or with other 
drugs; such as MDMA, ketamine, cannabis, N,N-disopropyl-5-
methoxytryptamine (``Foxy Methoxy'') and N,N-dipropyltryptamine (DPT).
    Information gathered by DEA indicates that 2C-T-7 has been 
purchased in powder form over the Internet and distributed as such. In 
the United States, capsules containing 2C-T-7 powder also have been 
encountered; whereas in the Netherlands (``Blue Mystics''), and in 
Canada (``Red Raspberry'') the bulk powder is being processed into 
tablets.
 

21 U.S.C. 811(c)(5) the Scope, Duration and Significance of Abuse



    State and local law enforcement agencies reported 2C-T-7 exhibits 
seized in the states of Texas and Wisconsin. In Wisconsin, two 
unrelated exhibits were submitted to the Wisconsin State Crime 
Laboratory for analysis; the first exhibit consisted of two clear 
capsules containing 16 to 18 milligrams of white powder and two paper 
packets. One packet contained 450 milligrams of tan powder and the 
other paper packet contained 869 milligrams. The powder in these 
exhibits was identified as 2C-T-7. These two capsules were sold to an 
informant as ``Tweety-Bird Mescaline.'' The second exhibit analyzed by 
the Wisconsin State Crime Laboratory was shown to be a mixture of 2C-T-
7 and N,N-dipropyltryptamine (DPT). 2C-T-7 has also appeared in illicit 
traffic in Tennessee, Washington, and Oklahoma, as evidenced by the 2C-
T-7 related deaths in these states. It is being sold under the ``street 
names'' Blue Mystic, T7, Beautiful, Tweety-Bird Mescaline or Tripstay. 
To date, DEA has not identified a clandestine laboratory synthesizing 
2C-T-7.
 

21 U.S.C. 811(c)(6) What, If Any, Risk There Is to Public Health

 

    2C-T-7 shares those structural similarities with 2CB and other 
phenethylamines (i.e., DOB, and DOM), which makes it likely to produce 
similar public health risks. Sensory distortion and impaired judgment 
can lead to serious consequences for both the user and the general 
public. 2C-T-7 can have lethal effects when abused alone or in 
combination with other illicit drugs. To date, three deaths have been 
associated with the abuse of 2C-T-7. The first death occurred in 
Oklahoma during April of 2000; a young healthy male overdosed on 2C-T-7 
following intranasal administration. The co-abuse of 2C-T-7 with MDMA 
will pose a significant health risk if 2C-T-7 popularity increases in 
the same venues as with MDMA. The co-abuse of 2C-T-7 with MDMA has 
resulted in lethal effects. The other two 2C-T-7 related deaths 
resulted from the co-abuse of 2C-T-7 with MDMA. They both occurred in 
April of 2001. One young man died in Tennessee while another man died 
in the state of Washington.
 

What Other Factors Were Taken Into Consideration?



    Additionally, DEA has considered the three criteria for placing a 
substance into Schedule I of the CSA (21 U.S.C. 812). The data 
available and reviewed for 2C-T-7 indicate that it has a high potential 
for abuse, no currently accepted medical use in treatment in the United 
States and is not safe for use under medical supervision. 

** end DEA quote **

 

Resources:

Entheogens and Drug Policy Project

Receive Top News Alerts in your E-mail box! >> Learn more